Skip to main content
SpringerLink
Log in

Special Populations: Protein Binding Aspects

  • Living reference work entry
  • First Online:
Drug Discovery and Evaluation: Methods in Clinical Pharmacology

  • 267 Accesses

Abstract

The aim of this chapter is to provide a basic understanding of the effect of protein binding and its alterations on the pharmacokinetics of drugs and their pharmacological and clinical effects. This has been matter of controversies in the last decades: this chapter calls for scientific comprehension of the underlying phenomena and recommends a reasoned experimental program aiming to the characterization of the protein binding of new compounds and the effects of its changes in different conditions. Considerations and data are also reported concerning the potential changes of drugs’ protein binding in some pathophysiological conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References and Further Reading

  • Ascenzi P, Fanali G, Fasano M, Pallottini V, Trezza V (2014) Clinical relevance of drug binding to plasma proteins. J Mol Struct 1077:4–13

    Article  CAS  Google Scholar 

  • Benet LZ (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71(3):115–121

    Article  CAS  Google Scholar 

  • Cheeti S, Budha NR, Rajan S, Dresser MJ, Jin JY (2013) A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharm Drug Dispos 34:141–54

    Article  CAS  Google Scholar 

  • Chu CYT, Singla VP, Wang HP, Sweet B, Lai LTY (1981) Plasma α1-acid glycoprotein levels in pregnancy. Clin Chim Acta 112:235–240

    Article  CAS  Google Scholar 

  • DeVane L (2002) Clinical significance of drug binding, protei binding, and binding displacement drug interactions. Psychopharmacol Bull 36:5–21

    Google Scholar 

  • Everson G, Lasseter KC, Anderson KE, Bauer LA, Carithens RL, Wilner KD, Johnson A, Anziano RJ, Smolarek TA, Turncliff RZ (2000) The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. Br J Clin Pharmacol 49:21–26

    Article  Google Scholar 

  • Grandison MK, Boudinot F (2000) D. Age-related changes in protein binding of drugs. Clin Pharmacokinet 38:271–290

    Article  CAS  Google Scholar 

  • Gugler R, Mueller G (1978) Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. Br J Clin Pharmacol 5:441–446

    Article  CAS  Google Scholar 

  • HervĂ© F, Urien S, Albengres E, DuchĂ© JC, Tillement JP (1994) Drug binding in plasma. Clin Pharmacokinet 26:44–58

    Article  Google Scholar 

  • Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L (2006) The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 46:88–102

    Article  CAS  Google Scholar 

  • Kovarik JM, Sabia HD, Figueiredo J, Zimmermann H, Reynolds C, Dilzer SC, Lasseter K, Rordorf C (2001) Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther 70:425–30, 2001

    Article  CAS  Google Scholar 

  • Lau AH, Gustavson LE, Sperelakis R, Lam NP, El-Shourbagy T, Qian JX, Layden T (1997) Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 38:445–451

    Article  CAS  Google Scholar 

  • Loebstein R, Lalkin A, Koren G (1997) Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 33:328–343

    Article  CAS  Google Scholar 

  • Lu H, Rosenbaum S (2014) Developmental pharmacokinetics in pediatric population. J Pediatr Pharmacol Ther 19:262–276

    PubMed  PubMed Central  Google Scholar 

  • McNamara PJ, Alcorn J (2002) Protein binding predictions in infants. AAPS PharmSci 4:19–26

    Article  Google Scholar 

  • Mehvar R (2005) Role of protein binding in pharmacokinetics. Am J Pharm Educ 69:103

    Article  Google Scholar 

  • Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B (2002) The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol 53:21S–30S

    Article  CAS  Google Scholar 

  • Musteata FM (2012) Calculation of normalized drug concentrations in the presence of altered plasma protein binding. Clin Pharm 51:55–68

    Article  CAS  Google Scholar 

  • Notarianni LJ (1990) Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet 18:20–36

    Article  CAS  Google Scholar 

  • Pang KS, Rowland M (1977) Hepatic clearance of drugs. II. Experimental evidence for acceptance of the “well-stirred” model over the “parallel tube” model using lidocaine in the perfused rat liver in situ preparation. J Pharmacokinet Biopharm 5:655–680

    Article  CAS  Google Scholar 

  • Peng JZ, Pulido F, Causemaker SJ, Li J, Lorenzo A, Cepeda C, Cabanillas JA, DaSilva B, Brun SC, Arribas J (2006) Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus–coinfected subjects with hepatic impairment. J Clin Pharmacol 46:265–274

    Article  CAS  Google Scholar 

  • Roberts JA, Pea F, Lipman J (2013) The clinical relevance of plasma protein binding changes. Clin Pharmacokinet 52:1–8

    Article  CAS  Google Scholar 

  • Rolan PE (1994) Plasma protein binding displacement interactions – why are they still regarded as clinically important? Br J Clin Pharmacol 37:125–128

    Article  CAS  Google Scholar 

  • Rowland M, Tozer TN, Derendorf H, Hochhaus G (2011a) Clinical pharmacokinetics and pharmacodynamics: concepts and applications, 4th edn. Wolters Kluwer Health/Lippincott William & Wilkins, Philadelphia, p 98

    Google Scholar 

  • Rowland M, Tozer TN, Derendorf H, Hochhaus G (2011b) Clinical pharmacokinetics and pharmacodynamics: concepts and applications, 4th edn. Wolters Kluwer Health/Lippincott William & Wilkins, Philadelphia, p 75

    Google Scholar 

  • Rowland M, Tozer TN, Derendorf H, Hochhaus G (2011c) Clinical pharmacokinetics and pharmacodynamics: concepts and applications, 4th edn. Wolters Kluwer Health/Lippincott William & Wilkins, Philadelphia, p 100

    Google Scholar 

  • Rowland M, Tozer TN, Derendorf H, Hochhaus G (2011d) Clinical pharmacokinetics and pharmacodynamics: concepts and applications, 4th edn. Wolters Kluwer Health/Lippincott William & Wilkins, Philadelphia, p 388

    Google Scholar 

  • Schmidt S, Gonzalez D, Derendorf H (2010) Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci 99:1107–1122

    Article  CAS  Google Scholar 

  • Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K (2008) Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 48:1411–1419

    Article  CAS  Google Scholar 

  • Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. In: European journal of clinical pharmacology, vol 64, pp 1147–1161

    Google Scholar 

  • Viani A, Rizzo G, Carrai M, Pacifici GM (1992) The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment. Br J Clin Pharmacol 33:299–304

    Article  CAS  Google Scholar 

  • Wallace SM, Verbeeck RK (1987) Plasma protein binding of drugs in the elderly. Clin Pharmacokinet 12:41–72

    Article  CAS  Google Scholar 

  • Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377–390

    Article  CAS  Google Scholar 

  • Zhang F, Xue J, Shao J, Jia L (2012) Compilation of 222 drugs’ plasma prtein binding data and guidance for study design. Drug Discov Today 17:475–485

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Global Clinical Pharmacology, Quantitative Sciences/Model-Based Drug Development, Cologno Monzese, Italy

    Italo Poggesi

Authors
  1. Italo Poggesi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Italo Poggesi .

Editor information

Editors and Affiliations

  1. CorDynamics , Dieburg, Germany

    Franz J. Hock

  2. CorDynamics , Chicago, IL, USA

    Michael R. Gralinski

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Poggesi, I. (2019). Special Populations: Protein Binding Aspects. In: Hock, F., Gralinski, M. (eds) Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-319-56637-5_10-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56637-5_10-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56637-5

  • Online ISBN: 978-3-319-56637-5

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation